"You just can't spread yourself thin."

Chris Prior, CEO of PhaseBio Pharmaceuticals Inc., on why his firm isn't seeking to supplement its venture funding with technology out-licensing deals

"We're still getting calls from venture capitalists . . . and these folks are as VC as VC gets."

Chris Lowe, chief financial officer of Anthera Pharmaceuticals Inc., on the continued interest of private investors in public companies

"All companies need to do to succeed is raise enough money, do it at a reasonable price, and get long-term holders."

Oleg Nodelman, portfolio manager and analyst at Biotechnology Value Fund LP, giving advice to IPO hopefuls